Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.

Literature DB >> 2803936

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.

D Pectasides¹, H Yianniotis, N Alevizakos, D Bafaloukos, V Barbounis, J Varthalitis, M Dimitriadis, A Athanassiou.

Abstract

Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin (CDDP) 120 mg m-2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and toxicity. There were five (19%) complete (CR) and seven (26%) partial (PR) responses for a total response rate of 45%. We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high rate of response in patients with advanced metastatic malignant melanoma, but responses are short.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1989 PMID： 2803936 PMCID： PMC2247122 DOI： 10.1038/bjc.1989.327

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

14 in total

1. Treatment of metastatic malignant melanoma with vinblastine, dacarbazine, and cisplatin: a report from the Cancer and Leukemia Group B.

Authors: R W Carey; J R Anderson; M Green; R R Ellison; L Nathanson; B J Kennedy
Journal: Cancer Treat Rep Date: 1986-03

2. Treatment of metastatic malignant melanoma with dacarbazine and cisplatin.

Authors: R Oratz; J L Speyer; M Green; R Blum; J C Wernz; F M Muggia
Journal: Cancer Treat Rep Date: 1987-09

3. Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study.

Authors: M A Friedman; D A Kaufman; J E Williams; K J Resser; E H Rosenbaum; R J Cohen; A B Glassberg; M R Blume; J Gershow; E Y Chan
Journal: Cancer Treat Rep Date: 1979-03

4. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.

Authors: L H Einhorn; M A Burgess; C Vallejos; G P Bodey; J Gutterman; G Mavligit; E M Hersh; J K Luce; E Frei; E J Freireich; J A Gottlieb
Journal: Cancer Res Date: 1974-08 Impact factor: 12.701

5. Phase II study of the combination of vinblastine, bleomycin, and cisplatin in advanced malignant melanoma.

Authors: E T Creagan; D L Ahmann; A J Schutt; S J Green
Journal: Cancer Treat Rep Date: 1982-03

6. DTIC (NSC-45388) studies in the southwest oncology group.

Authors: J J Costanzi
Journal: Cancer Treat Rep Date: 1976-02

7. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).

Authors: G J Hill; E T Krementz; H Z Hill
Journal: Cancer Date: 1984-03-15 Impact factor: 6.860

8. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.

Authors: S D Luikart; G T Kennealey; J M Kirkwood
Journal: J Clin Oncol Date: 1984-03 Impact factor: 44.544

9. Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin.

Authors: R M York; D H Lawson; J McKay
Journal: Cancer Date: 1983-12-15 Impact factor: 6.860

10. Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis.

Authors: K K Chary; D J Higby; E S Henderson; K D Swinerton
Journal: Cancer Treat Rep Date: 1977 May-Jun

5 in total

1. Epigenetic modulation and apoptotic induction by a novel imidazo-benzamide derivative in human lung adenocarcinoma cells.

Authors: Amrutha Arjunan; Sankar Pajaniradje; Arul Prakash Francis; Srividya Subramanian; Sathyapriya Chandramohan; D Parthasarathi; Ayyiliath M Sajith; M Syed Ali Padusha; P P Mathur; Rukkumani Rajagopalan
Journal: Daru Date: 2021-10-12 Impact factor: 4.088